Glyceryl Trinitrate
Coronary Artery Disorder
Shaanxi Buchang Pharmaceutical Co., LtdPhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
18 Active assets in the Coronary Artery Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Acetylsalicylic Acid Rajaie Cardiovascular Medical and Research Center | Phase 4 | BBB |
Ezetimibe Canadian Collaborative Research Network | Phase 4 | BBB |
SIMVASTATIN University of Washington | Phase 4 | BBB |
Rivaroxaban Sheffield Teaching Hospitals NHS Foundation Trust | Phase 4 | BBB |
Ranolazine OBS Pakistan | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Glyceryl Trinitrate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →